When Services May Be Eligible for Coverage

Coverage for eligible medical treatments or procedures, drugs, devices or biological products may be provided only if:

• Benefits are available in the member’s contract/certificate, and
• Medical necessity criteria and guidelines are met.

Based on review of available data, the Company may consider benralizumab (Fasenra™)‡ for add-on maintenance treatment of severe asthma (eosinophilic phenotype) to be eligible for coverage.

Patient Selection Criteria

- Coverage eligibility for benralizumab (Fasenra) will be considered for add-on maintenance treatment of severe asthma (eosinophilic phenotype) when the following criteria are met:

- Initial Authorization:
  I. Fasenra is being used for the treatment of severe asthma (eosinophilic phenotype); AND
  II. Patient is greater than or equal to 12 years of age; AND
  III. Fasenra is NOT being used in combination with other monoclonal antibodies typically used to treat asthma [e.g. reslizumab (Cinqair)‡, omalizumab (Xolair)‡, mepolizumab (Nucala)‡] AND
  IV. Fasenra is dosed at 30 mg every 4 weeks for the first 3 doses, followed by once every 8 weeks thereafter; AND
  V. Patient has a peripheral blood eosinophil count of greater than or equal to 300 cells per microliter within the past 6 weeks or within 6 weeks prior to treatment with any interleukin-5 (IL-5) antagonist monoclonal antibody [benralizumab (Fasenra), mepolizumab (Nucala), reslizumab (Cinqair)]; AND
  VI. Patient has received at least 3 consecutive months of combination therapy with BOTH of the following (a and b):
     (Note that the 3 month timeframe is an additional company requirement and will be denied as not medically necessary if not met);
     a) An inhaled corticosteroid (ICS) [e.g. fluticasone products (Flovent® HFA, Flovent® Diskus®), Arnuity™ Ellipta®‡], mometasone products (Asmanex® Twisthaler®, Asmanex® HFA)‡, flunisolide products (Aersopan™)‡, ciclesonide products (Alvesco®)‡, budesonide products (Pulmicort Flexhaler®)‡, beclomethasone products (QVAR®)‡; AND
     b) At least ONE of the following (1, 2, 3, OR 4)
        1) Inhaled long-acting beta-agonist (LABA) [e.g. salmeterol products (Serevent® Diskus®)]; OR
        NOTE: Use of a combination inhaler containing both an ICS and a LABA would fulfill the requirement for both criteria a. and b. [e.g. fluticasone propionate and salmeterol inhalation powder/aerosol (Advair® Diskus/HFA)‡, budesonide and formoterol fumarate inhalation aerosol (Symbicort®)‡, fluticasone furoate and...
Policy # 00606
Original Effective Date: 02/21/2018
Current Effective Date: 02/21/2018

vilarnterol inhalation powder (Breo® Ellipta®†), mometasone furoate and formoterol fumarate inhalation aerosol (Dulera®†).  
2) Inhaled long-acting muscarinic antagonist (LAMA) [e.g. tiotropium bromide inhalation spray (Spiriva® Respimat®†); OR 
3) Leukotriene receptor antagonist (LTRA) [e.g. montelukast tablets/granules (Singulair®, generics), zafirlukast tablets (Accolate®)]†; OR 
4) Theophylline (Theo-24, Uniphyl, TheoChron ER, generics); AND

VII. Patient's asthma continues to be uncontrolled as defined by ONE of the following (a, b, c, d, or e):
   a) The patient experienced two or more asthma exacerbations requiring treatment with systemic corticosteroids in the previous year; OR 
   b) The patient experienced one or more asthma exacerbation requiring hospitalization or an Emergency Department (ED) visit in the previous year; OR 
   c) Patient has a forced expiratory volume in 1 second (FEV1) < 80% predicted; OR 
   d) Patient has an FEV1/forced vital capacity (FVC) < 0.80; OR 
   e) The patient’s asthma worsens upon tapering of oral corticosteroid therapy.

Re-Authorization
Coverage continuation for benralizumab (Fasenra) will be considered for add-on maintenance treatment of severe asthma (eosinophilic phenotype) when the following criteria are met:
I. Fasenra is being used for the treatment of severe asthma (eosinophilic phenotype); AND 
II. Fasenra is NOT being used in combination with other monoclonal antibodies typically used to treat asthma [e.g. reslizumab (Cinqair), omalizumab (Xolair), mepolizumab (Nucala)]; AND 
III. Patient is greater than or equal to 12 years of age; AND 
IV. Fasenra is dosed at 30 mg every 8 weeks; AND 
V. Patient continues to receive the medications required in criterion VI. in the “Initial Criteria”; AND 
VI. Patient has responded to Fasenra therapy as determined by the prescribing physician [e.g., decreased asthma exacerbations; decreased asthma symptoms; decreased hospitalizations, emergency department (ED)/urgent care, or physician visits due to asthma; decreased requirement for oral corticosteroid therapy.]
(Note that this criterion is an additional company requirement and will be denied as not medically necessary if not met);

When Services Are Considered Not Medically Necessary
Based on review on available data, the Company considers the use of benralizumab (Fasenra) when the patient has NOT been on the pre-requisite medications for at least 3 consecutive months to be not medically necessary.**

Based on review on available data, the Company considers the continued use of benralizumab (Fasenra) when the patient has NOT responded to benralizumab (Fasenra) therapy as determined by the prescribing physician to be not medically necessary.**
Benralizumab (Fasenra™)

Policy # 00606
Original Effective Date: 02/21/2018
Current Effective Date: 02/21/2018

When Services Are Considered Investigational
Coverage is not available for investigational medical treatments or procedures, drugs, devices or biological products.

Based on review of available data, the Company considers the use of benralizumab (Fasenra) when the patient selection criteria are not met (with the exception of those denoted above as not medically necessary**) to be investigational.*

Based on review of available data, the Company considers the use of benralizumab (Fasenra) for indications other than the add-on maintenance treatment of severe asthma (eosinophilic phenotype) to be investigational.*

Background/Overview
Fasenra is an IL-5 antagonist monoclonal antibody (IgG1 kappa) indicated for add-on maintenance treatment of patients with severe asthma aged 12 years and older, with an eosinophilic phenotype. IL-5 is expressed on the surface of eosinophils and basophils. IL-5 is the major cytokine responsible for the growth and differentiation, recruitment, activation, and survival of eosinophils. Fasenra binds to IL-5, inhibiting the bioactivity of IL-5 by blocking its binding to the alpha chain of the IL-5 receptor complex. Inflammation is an important component in the pathogenesis of asthma. Multiple cell types (e.g., mast cells, eosinophils, neutrophils, macrophages, lymphocytes) and mediators (e.g., histamine, eicosanoids, leukotrienes, cytokines) are involved in inflammation. Fasenra, by inhibiting IL-5 signaling, reduces the production and survival of eosinophils; however, the mechanism of action in asthma has not been definitively established. Fasenra is provided in 30 mg/mL single dose prefilled syringes. Fasenra should be administered by a healthcare professional. The dosing of Fasenra is 30 mg every 4 weeks for the first three doses, followed by once every 8 weeks thereafter.

Asthma
Asthma is a respiratory disorder characterized by increased responsiveness of the trachea and bronchi to various stimuli resulting in the narrowing of the airways, along with mucous secretion. Symptoms vary in severity and intensity and include wheezing, cough and dyspnea. Attacks can be triggered by exercise, allergens, irritants and viral infections. Based on symptoms, the four levels of asthma severity are:

- Mild intermittent (comes and goes)—you have episodes of asthma symptoms twice a week or less, and you are bothered by symptoms at night twice a month or less; between episodes, however, you have no symptoms and your lung function is normal.
- Mild persistent asthma—you have asthma symptoms more than twice a week, but no more than once in a single day. You are bothered by symptoms at night more than twice a month. You may have asthma attacks that affect your activity.
- Moderate persistent asthma—you have asthma symptoms every day, and you are bothered by nighttime symptoms more than once a week. Asthma attacks may affect your activity.

©2018 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.
• Severe persistent asthma—you have symptoms throughout the day on most days, and you are bothered by nighttime symptoms often. In severe asthma, your physical activity is likely to be limited.

Treatment of asthma is based on a step up and step down approach based on the asthma severity and symptoms. Medications include short acting beta agonists for fast relief. Long term treatment centers around the use of inhaled corticosteroids and possible addition of medications such as long acting beta agonists, leukotriene receptor antagonists, inhaled long acting muscarinic antagonists, or theophylline.

**FDA or Other Governmental Regulatory Approval**

**U.S. Food and Drug Administration (FDA)**

Fasenra was approved in late 2017 for add-on maintenance treatment of patients with severe asthma aged 12 years and older, with an eosinophilic phenotype.

**Rationale/Source**

This medical policy was developed through consideration of peer-reviewed medical literature generally recognized by the relevant medical community, U.S. FDA approval status, nationally accepted standards of medical practice and accepted standards of medical practice in this community, Blue Cross and Blue Shield Association technology assessment program (TEC) and other non-affiliated technology evaluation centers, reference to federal regulations, other plan medical policies, and accredited national guidelines.

Fasenra had three confirmatory trials and one 12 week lung function trial. Trials 1 and 2 were randomized, double-blind, parallel-group, placebo controlled exacerbation trials in patients 12 years of age and older for 48 and 56 weeks, respectively. Patients were required to be on asthma medications (inhaled corticosteroids, long acting beta agonists, oral corticosteroids, etc.) and were also stratified as having a baseline eosinophil count of greater than or equal to 300 cells/microliter OR less than 300 cells per microliter. Fasenra was given per the package insert labeled dosing. The primary endpoint for these trials was the rate of asthma exacerbations in patients with baseline blood eosinophil counts of greater than or equal to 300 cells per microliter who were taking high dose inhaled corticosteroids and long acting beta agonists. In trial 1, 35% of patients receiving Fasenra experienced an asthma exacerbation compared to 51% on placebo. In trial 2, 40% of patients receiving Fasenra experienced an asthma exacerbation compared to 51% on placebo. In a subgroup analysis, reductions in exacerbation rates for those with baseline eosinophil counts greater than or equal to 300 cells/microliter showed a numerically greater response that those with a baseline count of less than 300 cells/microliter.

Trial 3 was a randomized, double-blind, parallel-group, oral corticosteroid reduction trial. Patients were required to have daily treatment with oral corticosteroids in addition to asthma inhalers. There was an 8 week run-in period during which the oral corticosteroid was titrated to the minimum effective dose without losing asthma control. Patients were required to have eosinophils greater than or equal to 150 cells/microliter and a history of at least one exacerbation. Fasenra was given as per the package insert dosing. The primary endpoint was the percent reduction from baseline of the final oral corticosteroid dose.
benralizumab (Fasenra™)

Policy #  00606
Original Effective Date:  02/21/2018
Current Effective Date:  02/21/2018

during weeks 24 to 28, while maintaining asthma control. Compared to placebo, patients receiving Fasenra achieved greater reductions in daily maintenance oral corticosteroid dose while maintaining asthma control. The median percent reduction in daily OCS dose from baseline was 75% in those receiving Fasenra compared to 25% in patients receiving placebo. Reductions of 50% or higher in oral corticosteroid dose were observed in 66% of those receiving Fasenra compared to 37% receiving placebo. The proportion of patients with a mean final dose less than or equal to 5 mg at weeks 24 to 28 was 59% for Fasenra and 33% for placebo. Only patients with an optimized baseline oral corticosteroid dose of 12.5 mg or less were eligible to achieve a 100% reduction in oral corticosteroid dose during the study. Of those patients, 52% receiving Fasenra and 19% on placebo achieved a 100% reduction in the oral corticosteroid dose.

Change from baseline in mean FEV₁ was assessed in these 3 trials as a secondary endpoint. Compared with placebo, Fasenra provided consistent improvements over time in the mean change from baseline in FEV₁.

References


Policy History

Original Effective Date:  02/21/2018
Current Effective Date:  02/21/2018
02/01/2018 Medical Policy Committee review
02/21/2018 Medical Policy Implementation Committee approval. New policy.
04/01/2018 Coding update
Next Scheduled Review Date:  02/2019

Coding

The five character codes included in the Blue Cross Blue Shield of Louisiana Medical Policy Coverage Guidelines are obtained from Current Procedural Terminology (CPT®), copyright 2017 by the American Medical Association (AMA). CPT is developed by the AMA as a listing of descriptive terms and five character identifying codes and modifiers for reporting medical services and procedures performed by physician.

The responsibility for the content of Blue Cross Blue Shield of Louisiana Medical Policy Coverage Guidelines is with Blue Cross and Blue Shield of Louisiana and no endorsement by the AMA is intended or should be implied. The AMA disclaims responsibility for any consequences or liability attributable or related to any use, nonuse or interpretation of information contained in Blue Cross Blue Shield of Louisiana Medical Policy Coverage Guidelines. Fee schedules, relative value units, conversion factors and/or related components are not assigned by the AMA, are not part of CPT, and the AMA is not recommending their use. The AMA does not directly or indirectly practice medicine or dispense medical services. The AMA assumes no liability for data contained or not contained herein. Any use of CPT outside of Blue Cross Blue Shield of Louisiana Medical Policy Coverage Guidelines should refer to the most current Current Procedural Terminology which contains the complete and most current listing of CPT codes and descriptive terms. Applicable FARS/DFARS apply.

©2018 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.
benralizumab (Fasenra™)

Policy #  00606
Original Effective Date:  02/21/2018
Current Effective Date:  02/21/2018

CPT is a registered trademark of the American Medical Association.

Codes used to identify services associated with this policy may include (but may not be limited to) the following:

<table>
<thead>
<tr>
<th>Code Type</th>
<th>Code</th>
</tr>
</thead>
<tbody>
<tr>
<td>CPT</td>
<td>No codes</td>
</tr>
<tr>
<td>HCPCS</td>
<td>J3490, J3590</td>
</tr>
</tbody>
</table>
                  Code added eff 4/1/18: C9466
| ICD-10 Diagnosis | J45.50-J45.52 |

*Investigational – A medical treatment, procedure, drug, device, or biological product is Investigational if the effectiveness has not been clearly tested and it has not been incorporated into standard medical practice. Any determination we make that a medical treatment, procedure, drug, device, or biological product is Investigational will be based on a consideration of the following:

A. Whether the medical treatment, procedure, drug, device, or biological product can be lawfully marketed without approval of the U.S. Food and Drug Administration (FDA) and whether such approval has been granted at the time the medical treatment, procedure, drug, device, or biological product is sought to be furnished; or

B. Whether the medical treatment, procedure, drug, device, or biological product requires further studies or clinical trials to determine its maximum tolerated dose, toxicity, safety, effectiveness, or effectiveness as compared with the standard means of treatment or diagnosis, must improve health outcomes, according to the consensus of opinion among experts as shown by reliable evidence, including:

1. Consultation with the Blue Cross and Blue Shield Association technology assessment program (TEC) or other nonaffiliated technology evaluation center(s);
2. Credible scientific evidence published in peer-reviewed medical literature generally recognized by the relevant medical community; or
3. Reference to federal regulations.

**Medically Necessary (or “Medical Necessity”) - Health care services, treatment, procedures, equipment, drugs, devices, items or supplies that a Provider, exercising prudent clinical judgment, would provide to a patient for the purpose of preventing, evaluating, diagnosing or treating an illness, injury, disease or its symptoms, and that are:

A. In accordance with nationally accepted standards of medical practice;
B. Clinically appropriate, in terms of type, frequency, extent, level of care, site and duration, and considered effective for the patient's illness, injury or disease; and
C. Not primarily for the personal comfort or convenience of the patient, physician or other health care provider, and not more costly than an alternative service or sequence of services at least as likely to produce equivalent therapeutic or diagnostic results as to the diagnosis or treatment of that patient's illness, injury or disease.

For these purposes, “nationally accepted standards of medical practice” means standards that are based on credible scientific evidence published in peer-reviewed medical literature generally recognized by the relevant medical community, Physician Specialty Society recommendations and the views of Physicians practicing in relevant clinical areas and any other relevant factors.

‡ Indicated trademarks are the registered trademarks of their respective owners.

NOTICE: Medical Policies are scientific based opinions, provided solely for coverage and informational purposes. Medical Policies should not be construed to suggest that the Company recommends, advocates, requires, encourages, or discourages any particular treatment, procedure, or service, or any particular course of treatment, procedure, or service.